The impact of China's National Drug Centralized Procurement Policy on pharmaceutical firm innovation: evidence from a staggered difference-in-differences analysis
{{output}}
Background: China's National Drug Centralized Procurement Policy (NDCPP) aims to reduce drug prices through a 'price-for-volume' mechanism. While effective in cost containment, its impact on pharmaceutical firms' innovation r... ...
